Last reviewed · How we verify
Placebo Vaccine
A placebo vaccine contains no active therapeutic agent and serves as a control comparator in clinical trials to establish the true efficacy of an investigational vaccine.
A placebo vaccine contains no active therapeutic agent and serves as a control comparator in clinical trials to establish the true efficacy of an investigational vaccine. Used for Control comparator in clinical trials (not a therapeutic indication).
At a glance
| Generic name | Placebo Vaccine |
|---|---|
| Also known as | Group 1, Group 2, Group 3, Group 4, Group 5 |
| Sponsor | Dana-Farber Cancer Institute |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Placebo vaccines are inert formulations used in randomized controlled trials to distinguish genuine therapeutic effects from placebo response and natural disease progression. They allow researchers to measure the incremental benefit of the active vaccine candidate by comparing outcomes between treatment and control groups receiving identical-appearing but inactive preparations.
Approved indications
- Control comparator in clinical trials (not a therapeutic indication)
Common side effects
- Injection site reactions
- Systemic adverse events consistent with natural disease progression
Key clinical trials
- A Clinical Trial Evaluating the Monkeypox Recombinant Protein Vaccine (PHASE1)
- A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults (PHASE3)
- Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1) (PHASE1)
- Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine in Healthy Adults (PHASE1)
- Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome (PHASE2)
- Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection (PHASE1)
- First-in-Human PfSPZ-LARC2 Vaccination/CHMI (PHASE1)
- Study of AV-1959D, an Amyloid Beta Vaccine (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo Vaccine CI brief — competitive landscape report
- Placebo Vaccine updates RSS · CI watch RSS
- Dana-Farber Cancer Institute portfolio CI